Effect of a Cannabinoid Agonist on Colonic Sensory Functions in Patients With Irritable Bowel Syndrome

Study on the Effect of Cannabinoid Agonist on Gastrointestinal and Colonic Motor and Sensory Functions in Patients With Diarrhea-Predominant Irritable Bowel Syndrome

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01786109

Enrollment

Registered

2013-02-07

Start date

2009-09-30

Completion date

2011-12-31

Last updated

2013-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

anandamide, cannabinoid, fatty acid amide hydrolase, gastric, motility, small bowel, sensory, motor

Brief summary

Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. There are still no effective and safe medications approved for the treatment of abdominal pain associated with bowel symptoms in IBS. This study will investigate the effects of an approved medication, Dronabinol, on the movement of food through the stomach and colon in subjects with a history of diarrhea-predominant Irritable Bowel Syndrome (D-IBS).

Detailed description

Irritable bowel syndrome (IBS) affects about 15% of the U.S. population. Despite increasing understanding of the pathophysiology of IBS, there is no effective medication approved for the treatment of abdominal pain associated with IBS. Cannabinoid receptors (CBR) are on cholinergic neurons in the brain stem, stomach and colon. A cannabinoid receptor 1 (CB1) antagonist, rimonabant, is effective in induction of weight loss; however, the mechanism of this benefit is unclear. Human studies from this lab show that a CBR agonist, dronabinol, inhibits gastric and colonic motility, which may alter appetite or satiation in obesity, and may have potential in the treatment of IBS. The overall focus of the study is on the mechanisms involved in the modulation of gastric and colonic motor and sensory functions by cannabinoid receptors (CBR) in health and in IBS. CB1 receptors are also involved in nociception and in mediating inflammation which are increasingly recognized as being potential pathophysiological mechanisms in IBS. All participants underwent the following procedures: 1. Documentation of eligibility, screening questionnaires and physical examination, including exclusion of rectal evacuation disorder by standard clinical evaluation within the past 12 months; this was important to ensure the diarrhea was not secondary to retention with overflow. 2. Bowel preparation with PEG and electrolyte-containing oral colonic lavage solution, followed by a 12 hour fast. 3. Colonic testing of compliance, tone, motility and sensation measurement. Colonic compliance, fasting tone, sensory thresholds and sensory ratings in response to random-order phasic distensions were performed before treatment was administered. Then medication was ingested, and after 60 minutes, the same studies were performed that is compliance, fasting tone, sensory thresholds and sensory ratings in response to random-order phasic distensions. Participants also filled in responses to questionnaires (using 100 mm VAS scales) to describe their sense of tiredness, peace, worry and activity at the time of the measurements of sensation. Finally, participants ingested a standard chocolate 1000 kcal milkshake meal, and postprandial colonic tone and motility were measured for one hour. 4. With appropriate consent, a venous blood sample was obtained from each participant for DNA extraction; this will be used in ongoing pharmacogenomics studies. Note: This study is related to NCT01253408, part A of the same protocol. Part A explored the effect of dronabinol on gastric and colonic motor functions.

Interventions

DRUGDronabinol

Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.

DRUGPlacebo

Placebo will match study drug; taken as one dose orally with water.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Age 18-75 years * Positive for IBS symptoms by Rome III criteria * No prior abdominal surgery (except appendectomy or cholecystectomy * Score of 10 or less on either Anxiety or Depression on the Hospital Anxiety/Depression Inventory

Exclusion criteria

* Patients with significant depression (score of greater than 10 on Hospital Depression Inventory * Patients with anxiety (score of greater than 10 on Hospital Anxiety Inventory. However, patients on stable doses of selective serotonin inhibitors (SSRIs) or low dose of tricyclic antidepressants will be eligible.

Design outcomes

Primary

Measure	Time frame	Description
Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)	1 hour after drug was ingested	Colonic compliance is a measure of the stiffness of the colon, that is, what pressure was needed to reach half the maximum volume of the colon. After the barostat catheter was inserted in the colon, the catheter was connected to a barostat machine. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg up to 64 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance.

Secondary

Measure	Time frame	Description
Post-treatment Sensory Threshold for First Perception of Pain	1 hour after drug was ingested	The sensory threshold for first perception of pain was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation.
Post-Treatment Overall Sensory Rating in Response to 16, 24, 32, and 40 mm Hg Distensions	1 hour after drug was ingested	The sensory rating was measured by a 100 mm long Visual Analog Scale (VAS). The VAS does not have any pre-set marks between the extremes of 0 for no pain and 100 mm for extreme pain. The investigator measures the mark made by the participant in mm and records this for the value of pain.
Fasting Colonic Tone	After 12 hour fast, before drug administered	Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon.)
Postprandial Change in Colonic Tone	1 hour after ingestion of standard meal	Colonic tone is a measurement of the volume of the colon. Colonic tone was assessed by noting the changes in the balloon volume in the presence of a constant operating pressure in the balloon (in the barostat-manometric assembly placed in the colon.)
Post-treatment Sensory Threshold for First Sensation	1 hour after drug was ingested	The sensory threshold for first sensation was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation.
Post-Treatment Sensory Threshold for First Perception of Gas	1 hour after drug was ingested	The sensory threshold for first perception of gas was measured by stepwise inflation in increments of 4 mm Hg at 60 second intervals up to a maximum pressure of 64 mm Hg. During this assessment participants were asked to report when they had the first sensation. The investigator recorded the threshold pressure at which the participants reported this sensation.
Postprandial Colonic Motility Index	1 hour after ingestion of standard meal	Colonic phasic pressure activity is summarized as a motility index (MI)=log\_e\[number of contractions \* sum of amplitudes) + 1\]. A normal fasting average motility index (MI) would be about 12. An increase in MI means an increase in the phasic contractions (in contrast to tone) which is measured as a change in volume of the barostat balloon. (Therefore, an increase in MI means that the meal is moving more quickly through the colon.)

Countries

United States

Participant flow

Recruitment details

All participants were recruited from a database of patients with irritable bowel syndrome (IBS) who reside within 120 miles of Rochester, Minnesota

Participants by arm

Arm	Count
Dronabinol 2.5 mg One dose of dronabinol 2.5 mg will be taken orally with water.	24
Dronabinol 5 mg One dose of dronabinol 5 mg will be taken orally with water.	24
Placebo One dose of placebo will be taken orally with water.	27
Total	75

Withdrawals & dropouts

Period	Reason	FG000	FG002
Overall Study	adverse effects colon preparation	0	1
Overall Study	fail manometry barostat tube placement	1	0
Overall Study	unrelated illness	0	1

Baseline characteristics

Characteristic	Dronabinol 2.5 mg	Dronabinol 5 mg	Placebo	Total
Age Continuous	36.1 years STANDARD_DEVIATION 2.5	43.7 years STANDARD_DEVIATION 2.1	43.2 years STANDARD_DEVIATION 2.5	40.8 years STANDARD_DEVIATION 11.935
Body Mass Index	26.7 kg/m^2 STANDARD_DEVIATION 1	29.7 kg/m^2 STANDARD_DEVIATION 1.1	28.9 kg/m^2 STANDARD_DEVIATION 1.2	28.3 kg/m^2 STANDARD_DEVIATION 5.5
Region of Enrollment United States	24 participants	24 participants	27 participants	75 participants
Sex: Female, Male Female	22 Participants	23 Participants	24 Participants	69 Participants
Sex: Female, Male Male	2 Participants	1 Participants	3 Participants	6 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk
deaths Total, all-cause mortality	— / —	— / —	— / —
other Total, other adverse events	10 / 24	13 / 24	10 / 27
serious Total, serious adverse events	0 / 24	0 / 24	0 / 27

Outcome results

Primary

Colonic Compliance at Pressure at Half-Maximum Volume (Pr 1/2)

Colonic compliance is a measure of the stiffness of the colon, that is, what pressure was needed to reach half the maximum volume of the colon. After the barostat catheter was inserted in the colon, the catheter was connected to a barostat machine. After an initial conditioning distension to 20 mm Hg, colonic compliance was measured by step-wise inflation with increments of 4 mm Hg up to 64 mm Hg. Colonic compliance was analyzed by a validated linear interpolation method. The pressure at half maximum volume serves as a summary of colonic compliance.

Time frame: 1 hour after drug was ingested